BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 22, 2018--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced it will be featured as a presenting company at the H. C.
Wainwright Annual Global Life Sciences Conference on April 8-10 at the
Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Antony Mattessich, President and Chief Executive Officer of Ocular
Therapeutix, will deliver a live presentation on the Company's pipeline
and business activities and will be available to participate in
one-on-one meetings with investors registered to attend the conference.
If you are an institutional investor, and would like to attend the
Company’s presentation, please click on the following link to register
for the conference (www.hcwevents.com).
Once your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with the Company.
Event: H. C. Wainwright Annual Global Life Sciences Conference
Presentation Date: April 9, 2018
Presentation Time: Monday, 2:35PM UTC
Location: Salon Atlantique; Le Meridien Beach Plaza Hotel in Monte
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
hydrogel-based formulation technology. Ocular Therapeutix’s lead product
candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular
use, has completed Phase 3 clinical development for the treatment of
ocular pain and inflammation following ophthalmic surgery. OTX-TP
(travoprost insert) is in Phase 3 clinical development for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral implant for the reduction of
intraocular pressure in patients with glaucoma and ocular hypertension,
as well as sustained release intravitreal implants for the treatment of
retinal diseases. These implants include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
an extended release protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
View source version on businesswire.com: https://www.businesswire.com/news/home/20180322006265/en/
Source: Ocular Therapeutix, Inc.
Senior Vice President, Commercial